NASPGHAN Practice guidelines: Diagnosis and management of hepatitis c infection in infants, children, and adolescents

Journal of Pediatric Gastroenterology and Nutrition

Volumn 54, Issue 6, 2012, Pages 838-855

  Mack, Cara L ^a   Gonzalez Peralta, Regino P ^b   Gupta, Nitika ^c   Leung, Daniel ^d   Narkewicz, Michael R ^a   Roberts, Eve A ^e   Rosenthal, Philip ^f   Schwarz, Kathleen B ^g  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g JOHNS HOPKINS CHILDREN S CENTER   (United States)

Author keywords

Chronic hepatitis; Infectious hepatitis; Interferon therapy; Pediatric liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CPT1A PROTEIN; DDX5 PROTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEPATITIS C ANTIBODY; IMMUNOGLOBULIN G; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PET INTRON REDIPEN; PROTEIN; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ANTICIPATORY GUIDANCE; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TRANSFUSION; BODY WEIGHT; BONE MARROW DEPRESSION; CANCER SCREENING; CD4+ T LYMPHOCYTE; CHILD; DEPRESSION; DIAGNOSTIC TEST; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; ENZYME IMMUNOASSAY; ERYTHEMA; GENETIC POLYMORPHISM; GENOTYPE; HEMATOLOGIC DISEASE; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; INFANT; INJECTION SITE REACTION; INSOMNIA; INSULIN DEPENDENT DIABETES MELLITUS; IRRITABILITY; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER HISTOLOGY; LIVER TRANSPLANTATION; MACULOPAPULAR RASH; MEDICAL HISTORY; MIXED INFECTION; MYALGIA; NAUSEA; NEUTROPENIA; OPTIC NERVE DISEASE; OPTIC NEURITIS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRISON; RENAL REPLACEMENT THERAPY; RETINOPATHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIDE EFFECT; SLEEP DISORDER; SUBSTANCE ABUSE; THROMBOCYTE COUNT; THYROID DISEASE; TREATMENT OUTCOME; VERTICAL TRANSMISSION; VIRUS GENOME; VIRUS TRANSMISSION; VISUAL IMPAIRMENT; VOMITING;

ADOLESCENT; CHILD; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INFANT; PEDIATRICS; SOCIETIES, MEDICAL;

HEPATITIS C VIRUS; RNA VIRUSES;

EID: 84861334032     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e318258328d     Document Type: Review

References (176)

1. Armstrong GL,Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-14. (Pubitemid 46780630)
2. Jhaveri R, Grant W, Kauf TL, et al. The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period. J Pediatr 2006;148:353-8.
3. Zou S, Tepper M, El Saadany S. Prediction of hepatitis C burden in Canada. Can J Gastroenterol 2000;14:575-80.
4. McQuillian GM, Kruszon-Moran D, Denniston MM, et al. Viral hepatitis. NCHS Data Brief 2010;27:1-8.
5. Chiquete E, Panduro A. Low prevalence of anti-hepatitis C virus antibodies in Mexico: a systematic review. Intervirology 2007;50:1-8. (Pubitemid 46005265)
6. Omland LH, Krarup H, Jepsen P, et al., DANVIR Cohort Study- Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study. J Hepatol 2010;53:36-42.
7. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the AASLD. Hepatology 2011;54:1433-44.
8. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Brit Med J 2008;336:924-6. (Pubitemid 351632017)
9. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaenous and treatment-induced viral clearance. Gastroenterology 2003;125:80-8. (Pubitemid 36799109)
10. Mast EE, Hwang LY, Seto DS, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis 2005;192:1880-9. (Pubitemid 41681885)
11. Yeung LT, To T, King SM, et al. Spontaneous clearance of childhood hepatitis C virus infection. J Viral Hepatol 2007;14:797-805. (Pubitemid 47561585)
12. Nainan OV, Alter MJ, Kruszon-Moran D, et al. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology 2006;131:478-84. (Pubitemid 44142463)
13. Murakami J, Okamoto M, Miyata H, et al. Evolution in the hypervariable region of hepatitis C virus in infants after vertical transmission. Pediatr Res 2000;48:450-6.
14. Farci P, Quinti I, Farci S, et al. Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively. Proc Natl Acad Sci USA 2006;103:8475-80. (Pubitemid 43838480)
15. Sullivan DG, Bruden D, Deubner H, et al. Hepatitis C virus dynamics during natural infection are associated with long-term histological outcome of chronic hepatitis C disease. J Infect Dis 2007;196:239-48. (Pubitemid 47047463)
16. Huang H, Shiffman ML, Cheung RC, et al. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology 2006;130:1679-87. (Pubitemid 43668836)
17. Mosbruger TL, Dugga P, Goedert JJ, et al. Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus. J Infect Dis 2010;201:1371-80.
18. Bosi I, Ancora G, Mantovani W, et al. HLA DR13 and HCV vertical infection. Pediatr Res 2002;51:746-9. (Pubitemid 34547339)
19. Martinetti M, Pacati I, Cuccia M, et al. Hierarchy of baby-linked immunogenetic risk factors in the vertical transmission of hepatitis C virus. Int J Immunopathol Pharmacol 2006;19:369-78. (Pubitemid 44181959)
20. Bevilacqua E, Fabris A, Floreano P, et al. Genetic factors in mother-tochild transmission of HCV infection. Virology 2009;390:64-70.
21. Della Bella S, Riva A, Tanzi E, et al. Hepatitis C virus-specific reactivity of CD4-lymphocytes in children born from HCV-infected women. J Hepatol 2005;43:394-402. (Pubitemid 41111419)
22. Ruiz-Extremera A, Munoz-Gamez JA, Salmeron-Ruiz MA, et al. Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children. Hepatology 2011;53:1830-8.
23. Waasdorp Hurtado C, Golden-Mason L, Brocato M, et al. Innate immune function in placenta and cord blood of hepatitis C-seropositive mother-infant dyads. PLoS One 2010;5:e12232.
24. Rumbo C, Fawaz RL, Emre SH, et al. Hepatitis C in children: a quaternary referral center perspective. J Pediatr Gastroenterol Nutr 2006;43:209-16. (Pubitemid 44180507)
25. Gonzalez-Peralta RP, Langham MR Jr, Andres JM, et al. Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2009;48:630-5.
26. Strickland DK, Jenkins JJ, Hudson MM. Hepatitis C infection and hepatocellular carcinoma after treatment of childhood cancer. J Pediatr Hematol Oncol 2001;23:527-9. (Pubitemid 33123705)
27. Lok AS, Seeff LB, Morgan TR, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009;136:138-48.
28. Madhoun MF, Fazili J, Bright BC, et al. Hepatitis C prevalence in patients with hepatocellular carcinoma without cirrhosis. Am J Med Sci 2010;339:169-73.
29. Forton DM, Thomas HC, Murphy CA, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology2002;35: 433-9. (Pubitemid 34106386)
30. Rodriguez JR, Balistreri W, Haber B, et al. Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes. J Pediatr Gastroenterol Nutr 2009;48:341-7.
31. Nydegger A, Srivastava A, Wake M, et al. Health-related quality of life in children with hepatitis C acquired in the first year of life. J Gastroenterol Hepatol 2008;23:226-30. (Pubitemid 351257659)
32. Hepatitis C virus infection. American Academy of Pediatrics. Committee on Infectious Diseases. Pediatrics 1998;101(3 Pt 1):481-5.
33. Luban NL, Colvin CA, Mohan P, et al. The epidemiology of transfusion- associated hepatitis C in a children's hospital. Transfusion 2007;47:615-20. (Pubitemid 46449621)
34. Moriya T, Sasaki F, Mizui M, et al. Transmission of hepatitis C virus from mothers to infants: its frequency and risk factors revisited. Biomed Pharmacother 1995;49:59-64.
35. Zanetti AR, Tanzi E, Paccagnini S, et al. Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission. Lancet 1995;345:289-91.
36. Okamoto M, Nagata I, Murakami J, et al. Prospective reevaluation of risk factors in mother-to-child transmission of hepatitis C virus: high virus load, vaginal delivery, and negative anti-NS4 antibody. J Infect Dis 2000;182:1511-4.
37. Resti M, Azzari C, Mannelli F, et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection. Brit Med J 1998; 317:437-41.
38. Conte D, Fraquelli M, Prati D, Minola E, et al. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology 2000;31:751-5. (Pubitemid 30118646)
39. Claret G, Noguera A, Esteva C, et al. Fortuny C.Mother-to-child transmission of hepatitis C virus infection in Barcelona, Spain: a prospective study. Eur J Pediatr 2007;166:1297-9. (Pubitemid 350029469)
40. Mast EE. Mother-to-infant hepatitis C virus transmission and breastfeeding. Adv Exp Med Biol 2004;554:211-6. (Pubitemid 39304513)
41. Yeung LT, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. Hepatology 2001;34:223-9. (Pubitemid 32702332)
42. Granovsky MO, Minkoff HL, Tess BH, et al. Hepatitis C virus infection in the mothers and infants cohort study. Pediatrics 1998; 102:355-9. (Pubitemid 28355001)
43. European Paediatric Hepatitis C Virus Network.A significant sex-but not elective cesarean section-effect on mother-to-child transmission of hepatitis C virus infection. J Infect Dis 2005;192:1872-9.
44. Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 1994;330:744-50. (Pubitemid 24080220)
45. Tajiri H, Miyoshi Y, Funada S, et al. Prospective study of mother-toinfant transmission of hepatitis C virus. Pediatr Infect Dis J 2001; 20:10-4. (Pubitemid 32066170)
46. Steininger C, Kundi M, Jatzko G, et al. Increased risk of mother-toinfant transmission of hepatitis C virus by intrapartum infantile exposure to maternal blood. J Infect Dis 2003;187:345-51. (Pubitemid 36184574)
47. Minola E, Maccabruni A, Pacati I, et al. Amniocentesis as a possible risk factor for mother-to-infant transmission of hepatitis C virus. Hepatol 2001;33:1341-2. (Pubitemid 32378240)
48. Ducarme G, Ceccaldi PF, Bernuau J, et al. [Amniocentesis and viral risk (hepatitis B, C virus and HIV)]. J Gynecol Obstet Biol Reprod (Paris) 2009;38:469-73.
49. Ferrero S, Lungaro P, Bruzzone BM, et al. Prospective study of mother-to-infant transmission of hepatitis C virus: a 10-year survey (1990-2000). Acta Obstet Gynecol Scand 2003;82:229-34.
50. Shiraki K, Ohto H, Inaba N, et al. Guidelines for care of pregnant women carrying hepatitis C virus and their infants. Pediatr Int 2008; 50:138-40. (Pubitemid 351239398)
51. Plunkett BA, Grobman WA. Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis. Am J Obstet Gynecol 2005;192:1153-61. (Pubitemid 40487793)
52. Haley RW, Fischer RP. Commercial tattooing as a potentially important source of hepatitis C infection: Clinical epidemiology of 626 consecutive patients unaware of their hepatitis C serologic status.Medicine (Baltimore) 2001;80:134-51. (Pubitemid 32285210)
53. Jara P, Resti M, Hierro L, et al. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis 2003;36:275-80. (Pubitemid 36169661)
54. Ackerman Z, Ackerman E, Paltiel O. Intrafamilial transmission of hepatitis C virus: a systematic review. J Viral Hepat 2000;7:93-103. (Pubitemid 30177099)
55. Mohamed MK, Magder LS, Abdel-Hamid M, et al. Transmission of hepatitis C virus between parents and children. Am J Trop Med Hyg 2006;75:16-20. (Pubitemid 351627563)
56. Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission? Hepatology 2010;52:1497-505.
57. Ketzinel-Gilad M, Colodner SL, Hadary R, et al. Transient transmission of hepatitis C virus from mothers to newborns. Eur J Clin Microbiol Infect Dis 2000;19:267-74. (Pubitemid 30255608)
58. Ceci O, Margiotta M, Marello F, et al. Vertical transmission of hepatitis C virus in a cohort of 2,447 HIV-seronegative pregnant women: a 24-month prospective study. J Pediatr Gastroenterol Nutr 2001;33:570-5. (Pubitemid 33151852)
59. Shebl FM, El-Kamary SS, Saleh DA, et al. Prospective cohort study of mother-to-infant infection and clearance of hepatitis C in rural Egyptian villages. J Med Virol 2009;81:1024-31.
60. Rerksuppaphol S, Hardikar W, Dore GJ. Long-term outcome of vertically acquired and post-transfusion hepatitis C infection in children. J Gastroenterol Hepatol 2004;19:1357-62. (Pubitemid 40052853)
61. Bortolotti F, Verucchi G, Camma C, et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology 2008;134:1900-7. (Pubitemid 351783258)
62. Casiraghi MA, De Paschale M, Romano L, et al. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology 2004;39:90-6. (Pubitemid 38461471)
63. Iorio R, Giannattasio A, Sepe A, et al. Chronic hepatitis C in childhood: an 18-year experience. Clin Infect Dis 2005;41:1431-7. (Pubitemid 41579984)
64. Vogt M, Lang T, Frosner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341:866-70. (Pubitemid 29427048)
65. Delgado-Borrego A, Healey D, Negre B, et al. Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection. J Pediatr Gastroenterol Nutr 2010;51:191-7.
66. Delgado-Borrego A, Jordan SH, Negre B, et al. Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol 2010;8:458-62.
67. Cesaro S, Bortolotti F, Petris MG, et al. An updated follow-up of chronic hepatitis C after three decades of observation in pediatric patients cured of malignancy. Pediatr Blood Cancer 2010;55:108-12.
68. Page K, Hahn JA, Evans J, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 2009;200:1216-26.
69. Serra MA, Escudero A, Rodriguez F, et al. Effect of hepatitis C virus infection and abstinence from alcohol on survival in patients with alcoholic cirrhosis. J Clin Gastroenterol 2003;36:170-4. (Pubitemid 36139733)
70. Wise M, Finelli L, Sorvillo F. Prognostic factors associated with hepatitis C disease: a case-control study utilizing U.S. multiplecause- of-death data. Public Health Rep 2010;125:414-22.
71. Beech BM, Myers L, Beech DJ. Hepatitis B and C infections among homeless adolescents. Fam Commun Health 2002;25:28-36.
72. Murray KF, Richardson LP, Morishima C, et al. Prevalence of hepatitis C virus infection and risk factors in an incarcerated juvenile population: a pilot study. Pediatrics 2003;111:153-7. (Pubitemid 36071046)
73. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease, Control and Prevention. MMWR Recomm Rep 1998;47 (RR-19):1-39.
74. England K, Pembrey L, Tovo PA, et al. Excluding hepatitis C virus (HCV) infection by serology in young infants of HCV-infected mothers. Acta Paediatr 2005;94:444-50.
75. Polywka S, Pembrey L, Tovo PA, et al. Accuracy of HCV-RNA PCR tests for diagnosis or exclusion of vertically acquired HCV infection. J Med Virol 2006;78:305-10. (Pubitemid 43132576)
76. American Academy of Pediatrics. 2006 Report of the Committee on Infectious Diseases, 27th ed. Hepatitis C. Elk Grove Village, IL: American Academy of Pediatrics; 2006: 355-359.
77. de Leuw P, Sarrazin C, Zeuzem S. How to use virological tools for the optimal management of chronic hepatitis C. Liver Int 2011;31 suppl 1:3-12.
78. Mukherjee S, Lin J, Bronze MS. Hepatitis C virus (HCV) assays are used to evaluate for HCV infection. Medscape 2011; 1996209.
79. Lee SR, Yearwood GD, Guillon GB, et al. Evaluation of a rapid, pointof- care test device for the diagnosis of hepatitis C infection. J Clin Virol 2010;48:15-7.
80. Lee SR, Kardos KW, Schiff E, et al. Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid. J Virol Methods 2011;172:27-31.
81. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74.
82. Halfon P, Bourliere M, Ouzan D, et al. A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus. J Gastroenterol Hepatol 2011; 23:931-5.
83. Gruppioni E, Vasuri F, Fiorentino M, et al. Real-time quantitative assay for routine testing of HCV RNA in formalin-fixed, paraffin-embedded liver samples. Diag Mol Pathol 2009;18:232-323.
84. Guido M, Rugge M, Jara P, et al. Chronic hepatitis C in children: the pathological and clinical spectrum. Gastroenterology 1998;115: 1525-9. (Pubitemid 28546004)
85. Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission? Hepatology 2010;52:1497-505.
86. Larzo MR, Poe SG. Adverse consequences of tattoos and body piercings. Pediatr Ann 2006;35:187-92.
87. Daniel AR, Shehab T. Transmission of hepatitis C through swapping body jewelry. Pediatrics 2005;116:1264-5. (Pubitemid 46056451)
88. Baizhanova Z, Ignatova TM, Nekrasova TP. [Metabolic syndrome and insulin resistance in patients with chronic hepatitis C]. Terapevticheskii arkhiv 2010;82:51-6.
89. Hwang SJ, Lee SD. Hepatic steatosis and hepatitis C: Still unhappy bedfellows? J Gastroenterol Hepatol 2011;26(suppl 1):96-101.
90. Peters MG, Terrault NA. Alcohol use and hepatitis C. Hepatology 2002;36 (5 suppl 1):S220-5. (Pubitemid 35253484)
91. Rose VL. AAP releases hepatitis C screening recommendations. Amer Fam Phys 1998;58:1218. (Pubitemid 28469046)
92. Pembrey L, Newell ML, Tovo PA. European paediatric hepatitis C virus network. Antenatal hepatitis C virus screening and management of infected women and their children: policies in Europe. Eur J Pediatr 1999;158:842-6. (Pubitemid 29448480)
93. European Paediatric Hepatitis C Virus Network. Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. Brit J Obstet Gynaecol 2001;108:371-7.
94. European Paediatric Hepatitis C Virus Network.A significant sex-but not elective cesarean section-effect on mother-to-child transmission of hepatitis C virus infection. J Inf Dis 2005; 192:1872-9.
95. Lin HH, Kao JH, Hsu HY, et al. Absence of infection in breast-fed infants born to hepatitis C virus-infected mothers. J Pediatr 1995; 126:589-91.
96. Resti M, Bortolotti F, Azzari C, et al. Transmission of hepatitis C virus from infected mother to offspring during subsequent pregnancies. J Pediatr Gastroenterol Nutr 2000;30:491-3. (Pubitemid 30307928)
97. Mok J, Pembrey L, Tovo PA, et al. When does mother to child transmission of hepatitis C virus occur? Arch Dis Child: Fetal Neonat Ed 2005;90:F156-60. (Pubitemid 40333086)
98. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19:1-46.
99. Camarero C, Ramos N, Moreno A, et al. Hepatitis C virus infection acquired in childhood. Eur J Pediatr 2008;167:219-24.
100. Goodman ZD, Makhlouf HR, Liu L, et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology 2008;47:836-43. (Pubitemid 351449675)
101. Gonzalez-Peralta RP, Kelly DA, Haber B, et al., International Pediatric Hepatitis C Therapy GroupInterferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology 2005;42:1010-8. (Pubitemid 43112667)
102. Schwarz KB, Gonzalez-Peralta RP, Murray KF, et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011;140:450-8.
103. Wirth S, Lang T, Gehring S, et al. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology 2002;36:1280-4. (Pubitemid 35253447)
104. Wirth S, Pieper-Boustani H, Lang T, et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005;41:1013-8. (Pubitemid 40593909)
105. Wirth S, Ribes-Koninckx C, Calzado MA, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010;52:501-7.
106. Christensson B, Wiebe T, Akesson A, et al. Interferon-alpha and ribavirin treatment of hepatitis C in children with malignancy in remission. Clin Infect Dis 2000;30:585-6. (Pubitemid 30205310)
107. Lackner H, Moser A, Deutsch J, et al. Interferon-alpha and ribavirin in treating children and young adults with chronic hepatitis C after malignancy. Pediatrics 2000;106:E53.
108. Schwarz KB, Mohan P, Narkewicz MR, et al. Safety, efficacy and pharmacokinetics of peginterferon alpha2a (40 kd) in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2006;43:499-505. (Pubitemid 44569011)
109. Tsunoda T, Inui A, Etani Y, et al., Working Group for the Study of Pegylated Monotherapy for Children with Chronic Hepatitis C in the Japan Society of Pediatric HepatologyEfficacy of pegylated interferonalpha2a monotherapy in Japanese children with chronic hepatitis C.Hepatol Res 2011;41:399-404.
110. Bekisz J, Schmeisser H, Hernandez J, et al. Human interferons alpha, beta and omega. Growth Factors 2004;22:243-51. (Pubitemid 40123402)
111. Feld J, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005;436:967-72. (Pubitemid 41191673)
112. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.
113. Lindsay KL, Trepo C, Heintges T, et al., Hepatitis Interventional Therapy GroupA randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403. (Pubitemid 32702353)
114. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92. (Pubitemid 28543496)
115. Poynard T, Marcellin P, Lee SS, et al. Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional TherapyGroup (IHIT). Lancet 1998;352:1426-32. (Pubitemid 28510876)
116. Lau JY, Tam RC, Liang TJ, et al. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002;35:1002-9. (Pubitemid 34453997)
117. Maag D, Castro C, Hong Z, et al. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem 2001;276:46094-8.
118. Crotty S, Maag D, Arnold JJ, et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000;6:1375-9. (Pubitemid 32001022)
119. Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010;138:116-22.
120. McHutchison JG, Lawitz EJ, Shiffman ML, et al., IDEAL Study TeamPeginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93.
121. Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010;138:108-15.
122. Sporea I, Danila M, Sirli R, et al. Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis. J Gastrointestin Liver Dis 2006;15:125-30. (Pubitemid 44011763)
123. Di Bisceglie AM, Shiffman ML, Everson GT, et al., HALT-C Trial InvestigatorsProlonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008;359:2429-41.
124. Sung H, Chang M, Saab S. Management of Hepatitis C antiviral therapy adverse events. Curr Hepatitis Rep 2011;10:33-40.
125. Foster GR. Quality of life considerations for patients with chronic hepatitis C. J Viral Hepat 2009;16:605-11.
126. Abdel-Aziz DH, Sabry NA, El-Sayed MH, et al. Efficacy and safety of pegylated interferon in children and adolescents infected with chronic hepatitis C: A preliminary study. J Pharm Prac 2011;24:203-10.
127. Yamane A, Nakamura T, Suzuki H, et al. Interferon-alpha-2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes. Blood 2008;112:542-50.
128. Pockros PJ, Duchini A, McMillan R, et al. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. Am J Gastroenterol 2002;97:2040-5.
129. Dourakis SP, Deutsch M, Hadziyannis SJ. Immune thrombocytopenia and alpha-interferon therapy. J Hepatol 1996;25:972-5.
130. DeFranceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31:997-1004. (Pubitemid 30169949)
131. Collantes RS, Younossi ZM. The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin. J Clin Gastroenterol 2005;39:S9-13.
132. Egrie JC, Dwyer E, Browne JK, et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003;31:290-9. (Pubitemid 36407605)
133. Adamson J. Erythropoietin, iron metabolism, and red blood cell production. Semin Hematol 1996;33:5-7.
134. Allon M, Kleinman K, Walczyk M, et al. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clin Pharmacol Ther 2002;72:546-55. (Pubitemid 36237726)
135. Dieterich DT, Wasserman R, Braü N, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003;98:2491-9. (Pubitemid 37448762)
136. Sulkowski MS, Dieterich DT, Bini EJ, et al., for the HIV/HCV Coinfection Study GroupEpoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ ribavirin: a randomized controlled trial. J Acquir Immune Defic Syndr 2005;39:504-6. (Pubitemid 41003802)
137. Van Vlerken LG, Van Soest H, Janssen MP, et al. Suboptimal endogenous erythropoietin response in chronic hepatitis C patients during ribavirin and PEG interferon treatment. Eur J Gastroenterol Hepatol 2010;22:1308-15.
138. Sievert W, Dore GJ, McCaughan GW, et al., CHARIOT Study GroupVirological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. Hepatology 2011;53: 1109-17.
139. Afdhal NH, Dieterich DT, Pockros PJ, et al., Proactive Study Group- Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology2004;126:1302-11. (Pubitemid 38552795)
140. Pockros PJ, Shiffman ML, Schiff ER, et al., PROACTIVE Study GroupEpoetin alfa improves quality of life in anemic HCVinfected patients receiving combination therapy. Hepatol 2004;40: 1450-8. (Pubitemid 39657021)
141. Shiffman ML, Salvatore J, Hubbard S, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007;46:371-9. (Pubitemid 47344771)
142. Cash WJ, Patterson K, Callender ME, et al. Adjuvant therapy used in conjunction with combination therapy for chronic hepatitis C improves sustained virus response rates in genotype 1 patients. J Viral Hepat 2010;17:269-73.
143. Ong JP, Younossi ZM. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. Cleve Clin J Med 2004;71:S17-21. (Pubitemid 41315602)
144. Sulkowski MS. Management of the hematologic complications of hepatitis C therapy. Clin Liver Dis 2005;9:601-16. (Pubitemid 41406390)
145. Al-Huthail YR. Neuropsychiatric side-effects of interferon alfa therapy for hepatitis C and their management: a review. Saudi J Gastroenterol 2006;12:59-67.
146. Hsieh MC, Yu ML, Chuang WL, et al. Virologic factors related to interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C. Eur J Endocrinol 2000;142:431-7.
147. Mehta N, Murthy UK, Kaul V, et al. Outcome of retinopathy in chronic hepatitis C patients treated with peginterferon and ribavirin. Dig Dis Sci 2010;55:452-7.
148. Narkewicz MR, Rosenthal P, Schwarz KB, et al., PEDS-C Study GroupOphthalmologic complications in children with chronic hepatitis C treated with pegylated interferon. J Pediatr Gastroenterol Nutr 2010;51:183-6.
149. Veluru C, Atluri D, Chadalavada R, et al. Skin rash during chronic hepatitis C therapy. Gastroenterol Hepatol 2010;6:323-5.
150. Mistry N, Shapero J, Crawford RI. A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin. Can J Gastroenterol 2009;23:677-83.
151. Ward RP, Kugelmas M. Using pegylated interferon and ribavirin to treat patients with chronic hepatitis C. Am Fam Phys 2005;72:655-62. (Pubitemid 41176774)
152. Barlow CF, Priebe CJ, Mulliken JB, et al. Spastic diplegia as a complication of interferon a-2a treatment of hemangiomas of infancy. J Pediatr 1998;132:527-30. (Pubitemid 28180264)
153. Zanini B, Covolo L, Donato F, et al. Effectiveness and tolerability of combination treatment of chronic hepatitis C in illicit drug users: metaanalysis of prospective studies. Clin Ther 2010;32:2139-59.
154. Hong BA, North CS, Pollio DE, et al. The use of psychoeducation for a patient with hepatitis C and psychiatric illness in preparation for antiviral therapy: a case report and discussion. J Clin Psychol Med Settings 2011;18:99-107.
155. Tural C, Galeras JA, Planas R, et al. Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)- monoinfected and HCV-HIV-coinfected patients. Antivir Ther 2008; 13:1047-55.
156. Mofenson LM, Brady MT, Danner SP, et al. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIVexposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep 2009;58:1-166.
157. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations fromthe HCV-HIV International Panel. AIDS 2007;21:1073-89.
158. England K, Thorne C, Pembrey L, et al. Policies and practices for the clinical management of HIV/HCV coinfected children in Europe: an epidemiological survey. Eur J Pediatr 2009;168:915-7.
159. Zampino R, Marrone A, Merola A, et al. Long-term outcome of hepatitis B and hepatitis C virus co-infection and single HBVinfection acquired in youth. J Med Virol 2009;81:2012-20.
160. Harmatz P, Jonas MM, Kwiatkowski JL, et al. Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematologica 2008; 93:1247-51.
161. Ferrell LD, Wright TL, Roberts J, et al. Hepatitis C viral infection in liver transplant recipients. Hepatology 1992;16:865-76.
162. Barshes NR, Udell IW, Lee TC, et al. The natural history of hepatitis C virus in pediatric liver transplant recipients. Liver Transplant 2006; 12:1119-23. (Pubitemid 44063787)
163. Arango J, Arbelaez M, Henao J, et al. Kidney graft survival in patients with hepatitis C: a single center experience. Clin Transplant 2008; 22:16-9. (Pubitemid 351149997)
164. Pereira BJ, Natov SN, Bouthot BA, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int 1998;53:1374-81. (Pubitemid 28316901)
165. Schmitz V, Kiessing A, Bahra M, et al. Peginterferon alfa-2b plus ribavirin for the treatment of hepatitis C recurrence following combined liver and kidney transplantation. Ann Transplant 2007;12:22-7.
166. Baid S, Cosimi AB, Tolkoff-Rubin N, et al. Renal disease associated with hepatitis C infection after kidney and liver transplantation. Transplantation 2000;70:255-61. (Pubitemid 30602737)
167. Baid S, Tolkoff-Rubin N, Saidman S, et al. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant 2003;3:74-8. (Pubitemid 36306827)
168. Liu CH, Kao JH. Treatment of hepatitis C virus infection in patients with end-stage renal disease. J Gastroenterol Hepatol 2011;26:228-39.
169. Vezali E, Aghemo A, Colombo M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther 2010;32:2117-38.
170. Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005;42:255-62. (Pubitemid 41061075)
171. Soriano V, Vispo E, Poveda E, et al. Directly acting antivirals against hepatitis C virus. J Antimicrob Chemother 2011;66:1673-86.
172. Vermehren J, Sarrazin C. New HCV therapies on the horizon. Clin Microbiol Infect 2011;17:122-34.
173. Lemon SM, McKeating JA, Pietschmann T, et al. Development of novel therapies for hepatitis C. Antiviral Res 2010;86:79-92.
174. Jacobson IM, McHutchison JG, Dusheiko G, et al., ADVANCE Study TeamTelaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
175. Poordad F, McCone J Jr, Bacon BR, et al., SPRINT-2 Investigators- Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
176. Clark PJ, Thompson AJ, McHutchison JG. IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. Am J Gastroenterol 2011;106:38-45.